Hodgkin’s cells express CD83, a dendritic cell lineage associated antigen

Sorg, Ursula R.; Morse, Timothy M.; Patton, W. N.; Hock, Barry D.; Angus, Helen; Robinson, Bridget A.; Colls, B. M.; Hart, Derek N.J.

doi:10.1080/00313029700169125

Cited by 51 publications

(24 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In situ, CD83 expression is only detectable on some germinal center lymphocytes with immunohistochemistry staining, although CD83 transcripts are detectable in activated human B cells and at lower levels in human brain and lung tissue [1,17]. The malignant cells of Hodgkin's disease and Epstein-Barr virus transformed lymphoblastoid cell lines also express CD83 [20,21]. Thus, low level CD83 expression by human lymphocytes can be induced upon cellular activation.…”

Section: Cd83 Expressionmentioning

confidence: 99%

Dendritic cell CD83: A therapeutic target or innocent bystander?

Prazma

Tedder

2008

Immunology Letters

View full text Add to dashboard Cite

CD83 represents an intriguing target for immunotherapy due to its preferential expression on mature DCs, the most efficient of antigen presenting cells. Based on its restricted expression pattern, structure, and the paucity of CD4 + T cells in CD83-deficient mice, multiple immunologically important functions for CD83 during immune responses have been proposed. Indeed, several studies have reported that CD83 blockade using soluble receptor constructs inhibits T cell responses in vitro and in vivo, can affect autoimmune disease development and progression, and can inhibit transplant rejection. However, others have not been able to reproduce some of these findings, and antigen presenting cells deficient in CD83 expression or expressing a mutated form of CD83 induce normal T cell responses in vitro. This review examines the controversy surrounding CD83 function, alleged CD83 ligands, the potential therapeutic utility of recombinant proteins targeting CD83 function, and the importance of soluble serum CD83. While the validity of multiple previous studies needs to be confirmed, CD83 remains a fascinating cell surface molecule with a unique pattern of expression that has multiple confirmed functions in regulating immune system development and function.

show abstract

Section: Cd83 Expressionmentioning

confidence: 99%

Dendritic cell CD83: A therapeutic target or innocent bystander?

Prazma

Tedder

2008

Immunology Letters

View full text Add to dashboard Cite

show abstract

“…It was also shown that CD83 is expressed on polymorphonuclear neutrophils (11) and on murine thymus epithelial cells (12). Furthermore, CD83 is expressed on Hodgkin cells (13) and EBVtransformed lymphoblastoid cell lines (2,14).…”

mentioning

confidence: 99%

Alternative Splicing Generates Putative Soluble CD83 Proteins That Inhibit T Cell Proliferation

Dudziak¹,

Nimmerjahn²,

Bornkamm³

et al. 2005

The Journal of Immunology

View full text Add to dashboard Cite

CD83 is expressed on mature dendritic cells and activated lymphocytes and has been implicated to play an important role during T cell development in the thymus. In contrast, not much is known about the function of CD83 in the periphery. Soluble forms of CD83 have been detected in the serum, but neither the function nor the mechanism of how these soluble forms of CD83 are generated are fully understood. In this study, we report the identification of four different transcripts of CD83 in unstimulated PBMCs. Sequence analysis demonstrated that the longest form codes for transmembrane CD83 (CD83-TM), whereas the smaller transcripts are splice variants of full-length CD83, coding for putative soluble CD83 proteins. Stimulation of PBMCs with PHA, TNF-α, or LPS leads to the up-regulation of the full-length CD83 transcript and to a strong down-regulation of two of the three smaller transcripts. The smallest CD83 splice product can be translated efficiently into protein, and recombinant soluble CD83 shows a strong inhibitory effect on T cell proliferation in MLRs. Our results suggest that the constitutive production of soluble forms of CD83 under steady-state conditions may have an important function in regulating immune homeostasis.

show abstract

“…CD83 is a member of the Ig superfamily with one extracellular Ig V-like domain and largely conserved nucleotide and amino acid sequence homologies between human and mouse (1, 9 -11). Cell surface CD83 is upregulated during the maturation of human DCs (1, 2, 4 -6, 8), is expressed by malignant Hodgkin's cells (12), and is expressed transiently by human monocytes and macrophages (5,6,13,14). Cell surface CD83 is only expressed weakly by a population of human germinal center lymphocytes in vivo (1) and by mitogenactivated lymphocytes in vitro (1,9,15), and at low levels by a number of human B and T cell lines (1,9).…”

mentioning

confidence: 99%

CD83 Expression Is a Sensitive Marker of Activation Required for B Cell and CD4+ T Cell Longevity In Vivo

Prazma

Yazawa

Fujimoto

et al. 2007

The Journal of Immunology

View full text Add to dashboard Cite

CD83 is a surface marker that differentiates immature and mature human dendritic cell populations. Thymic epithelial cell expression of CD83 is also necessary for efficient CD4+ T cell development in mice. The altered phenotypes of peripheral B and CD4+ T cells, and the reduction of peripheral CD4+ T cells in CD83−/− mice, suggest additional functions for CD83. To assess this, a panel of mAbs was generated to characterize mouse CD83 expression by peripheral leukocytes. As in humans, activation of conventional and plasmacytoid murine dendritic cell subsets led to rapid up-regulation of CD83 surface expression in mice. In primary and secondary lymphoid compartments, a subset of B cells expressed low-level CD83, while CD83 was not detected on resting T cells. However, CD83 was prominently up-regulated on the majority of spleen B and T cells within hours of activation in vitro. In vivo, a low dose of hen egg lysozyme (1 μg) induced significant CD83 but not CD69 expression by Ag-specific B cells within 4 h of Ag challenge. Although B cell development appeared normal in CD83−/− mice, B and CD4+ T cell expression of CD83 was required for lymphocyte longevity in adoptive transfer experiments. Thus, the restricted expression pattern of CD83, its rapid induction following B cell and T cell activation, and its requirement for B cell and CD4+ T cell longevity demonstrate that CD83 is a functionally significant and sensitive marker of early lymphocyte activation in vivo.

show abstract

Hodgkin’s cells express CD83, a dendritic cell lineage associated antigen

Cited by 51 publications

References 40 publications

Dendritic cell CD83: A therapeutic target or innocent bystander?

Dendritic cell CD83: A therapeutic target or innocent bystander?

Alternative Splicing Generates Putative Soluble CD83 Proteins That Inhibit T Cell Proliferation

CD83 Expression Is a Sensitive Marker of Activation Required for B Cell and CD4+ T Cell Longevity In Vivo

Contact Info

Product

Resources

About